HCPCS S3854 is officially defined as "Gene expression profiling panel for use in the management of breast cancer treatment." HCPCS S3854 is referenced in 4 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, Blue Shield of California, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS S3854 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield Rhode Island is implementing major policy changes effective January 1, 2026, including new prior authorization requirements for physical therapy after 14 visits, removing prior authorization from numerous cardiology/radiology procedures, and updating coverage for various genetic testing and specialty procedures. Multiple CPT codes are changing authorization status and coverage requirements across Medicare Advantage and commercial plans.
Blue Shield of California medical policy 2.04.36, on assays of genetic expression in tumor tissue to determine prognosis in patients with breast cancer, has an effective date of November 1, 2026. The policy history lists that date as an annual review in which the policy statement and literature were updated. The policy addresses Oncotype DX, EndoPredict, Breast Cancer Index, MammaPrint and Prosigna, lists the criteria under which these tests may be considered medically necessary for adjuvant chemotherapy decisions, and states that all other indications are investigational.
Excellus BlueCross BlueShield medical policy 2.02.27 has a current effective date of April 16, 2026. Oncotype Dx Breast Recurrence Score and the MammaPrint 70-gene panel are considered medically appropriate to guide the decision about adjuvant chemotherapy for newly diagnosed breast cancer when all listed criteria are met, including unilateral disease, hormone receptor positive and HER2 negative status, Stage 1 or Stage 2 disease, three or fewer positive axillary nodes, no distant metastasis, and an assay ordered within six months after diagnosis. Breast Cancer Index, Prosigna and EndoPredict are considered medically appropriate under separate criteria for axillary lymph node-negative disease. All other gene expression classifiers, such as Oncotype DX Breast DCIS Score, DCISionRT, AidaBreast and PreciseDx, are considered investigational for breast cancer. The 2026 annual review made no change to policy intent and added PLA code 0630U.
Gene expression assays, including the Oncotype DX colon cancer test, for determining the prognosis of stage 2 or stage 3 colon cancer following surgery are considered investigational. Circulating tumor DNA assays for determining the prognosis of stage 2 or stage 3 colon cancer following surgery are also considered investigational.
Watch S3854
Get one email when a payer policy names S3854, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for S3854
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for S3854 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.